Alnylam Pharmaceuticals Inc (ALNY)vsCelularity Inc (CELU)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
CELU
Celularity Inc
$1.02
-3.77%
HEALTHCARE · Cap: $28.80M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 16047% more annual revenue ($4.29B vs $26.55M). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
CELU
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+73.7%
Fair Value
$4.68
Current Price
$1.02
$3.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -6367.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CELU
The strongest argument for CELU centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a growth stock while CELU is a value play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.48 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 18/100) and 96.4% revenue growth. CELU offers better value entry with a 73.7% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a forward-thinking biotechnology company focused on advancing regenerative medicine through its unique cellular products derived from the placenta. The company is advancing a comprehensive pipeline of innovative immunotherapies designed to provide allogeneic off-the-shelf solutions that enhance treatment effectiveness while reducing complications for cancer and other serious diseases. With a strong management team and strategic partnerships, Celularity aims to address significant unmet medical needs, positioning itself as a key player in the evolving field of advanced therapeutics.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?